NWBO Share Price Performance
US$0.25
-0.03 (-9.03%)
Price US$0.25
Share Pricen/a
Northwest Biotherapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
NWBO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Northwest Biotherapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.059
- -3,502.35%
- -9,735.75%
- -75.8%
About NWBO
- Founded
- 1996
- Employees
- 25
- CEO
- WebsiteView website
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
